PMPRB releases three new NPDUIS reports

Smart & Biggar

As part of the National Prescription Drug Utilization Information System (NPDUIS) initiative, the Patented Medicine Prices Review Board (PMPRB) has released three reports:

  1. Market Intelligence Report: Combination Inhalers for Asthma, 2018: This report analyzes the market for inhaled corticosteroid and long-acting beta agonist combination inhalers used in the treatment of asthma, the most chronic respiratory disease in Canada. The report centres on 2018, and analyzes the use, pricing and market share of these medicines, in Canadian markets and places them in an international context
  2. Biologics in Canada, 2018: Part 1: Market Trends, 2018 examines the Canadian market for biologics, with a comparison to international trends in sales, pricing and biosimilar uptake. Part 2: Biosimilar Savings, 2018 uses trends in Canada and internationally to examine cost savings that could be realized through increasing the uptake and/or lowering the prices of biosimilars in Canada.
  3. Meds Pipeline Monitor, 2019: This report, released on April 21, 2020, is “a horizon scanning report that features a selection of new medicines in the late stages of clinical evaluation that may have a significant impact on future clinical practice and drug spending in Canada” (see news release).

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Smart & Biggar | Attorney Advertising

Written by:

Smart & Biggar

Smart & Biggar on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.